| Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis SL Spencer, S Gaudet, JG Albeck, JM Burke, PK Sorger Nature 459 (7245), 428-432, 2009 | 1138 | 2009 |
| Physicochemical modelling of cell signalling pathways BB Aldridge, JM Burke, DA Lauffenburger, PK Sorger Nature cell biology 8 (11), 1195-1203, 2006 | 737 | 2006 |
| Quantitative analysis of pathways controlling extrinsic apoptosis in single cells JG Albeck, JM Burke, BB Aldridge, M Zhang, DA Lauffenburger, ... Molecular cell 30 (1), 11-25, 2008 | 438 | 2008 |
| Modeling a snap-action, variable-delay switch controlling extrinsic cell death JG Albeck, JM Burke, SL Spencer, DA Lauffenburger, PK Sorger PLoS biology 6 (12), e299, 2008 | 351 | 2008 |
| Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks DC Kirouac, J Saez-Rodriguez, J Swantek, JM Burke, DA Lauffenburger, ... BMC systems biology 6, 1-17, 2012 | 86 | 2012 |
| Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation DS Jones, AP Jenney, JL Swantek, JM Burke, DA Lauffenburger, ... Nature chemical biology 13 (1), 38-45, 2017 | 64 | 2017 |
| Systematic calibration of a cell signaling network model KA Kim, SL Spencer, JG Albeck, JM Burke, PK Sorger, S Gaudet, DH Kim BMC bioinformatics 11, 1-14, 2010 | 61 | 2010 |
| Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase … BS Hendriks, J Cook, JM Burke, JM Beusmans, DA Lauffenburger, ... IEE Proceedings-Systems Biology 153 (1), 22-33, 2006 | 44 | 2006 |
| Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: scientific rationale and review CD Barrett, HB Moore, EE Moore, RC McIntyre, PK Moore, J Burke, F Hua, ... Research and Practice in Thrombosis and Haemostasis 4 (4), e12357, 2020 | 43 | 2020 |
| Quantitative systems toxicology P Bloomingdale, C Housand, JF Apgar, BL Millard, DE Mager, JM Burke, ... Current opinion in toxicology 4, 79-87, 2017 | 36 | 2017 |
| Quantitative systems pharmacology model of hUGT1A1‐modRNA encoding for the UGT1A1 enzyme to treat Crigler‐Najjar syndrome type 1 JF Apgar, JP Tang, P Singh, N Balasubramanian, J Burke, MR Hodges, ... CPT: pharmacometrics & systems pharmacology 7 (6), 404-412, 2018 | 34 | 2018 |
| Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC. HA Burris, MK Callahan, AW Tolcher, S Kummar, GS Falchook, ... Journal of Clinical Oncology 35 (15_suppl), 3033-3033, 2017 | 30 | 2017 |
| Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease K Madrasi, R Das, H Mohmmadabdul, L Lin, BT Hyman, ... Alzheimer's & Dementia 17 (9), 1487-1498, 2021 | 12 | 2021 |
| Quantitative systems pharmacology model of a masked, tumor‐activated antibody M Stroh, J Sagert, JM Burke, JF Apgar, L Lin, BL Millard, WM Kavanaugh CPT: Pharmacometrics & Systems Pharmacology 8 (9), 676-684, 2019 | 11 | 2019 |
| Model‐informed drug development of the masked Anti‑PD‑L1 antibody CX‐072 M Stroh, M Green, BL Millard, JF Apgar, JM Burke, W Garner, H Lu, ... Clinical Pharmacology & Therapeutics 109 (2), 383-393, 2021 | 10 | 2021 |
| An introduction to the regulatory and nonclinical aspects of the nonclinical development of antibody drug conjugates JA Lansita, JM Burke, JF Apgar, B Mounho-Zamora Pharmaceutical research 32 (11), 3584-3592, 2015 | 5 | 2015 |
| Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid L Lin, F Hua, C Salinas, C Young, T Bussiere, JF Apgar, JM Burke, ... CPT: pharmacometrics & systems pharmacology 11 (3), 362-372, 2022 | 3 | 2022 |
| CORRIGENDUM: Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1 JF Apgar, JP Tang, P Singh, N Balasubramanian, JM Burke, MR Hodges, ... CPT: Pharmacometrics & Systems Pharmacology 9 (3), 185, 2020 | 3 | 2020 |
| A quantitative systems pharmacology model of colonic motility with applications in drug development R Das, L Wille, L Zhang, C Chen, W Winchester, J Selimkhanov, ... Journal of Pharmacokinetics and Pharmacodynamics 46, 485-498, 2019 | 3 | 2019 |
| Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer H Sayama, D Marcantonio, T Nagashima, M Shimazaki, T Minematsu, ... CPT: Pharmacometrics & Systems Pharmacology 10 (8), 864-877, 2021 | 2 | 2021 |
